Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al
- 23 September 2021
- journal article
- letter
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (10) , 2644-2646
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumabJournal of Thrombosis and Haemostasis, 2021
- Redefining outcomes in immune TTP: an international working group consensus reportBlood, 2021
- Real-world experience with caplacizumab in the management of acute TTPBlood, 2021
- Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve OutcomesJournal of Blood Medicine, 2020
- Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpuraDrug Design, Development and Therapy, 2019
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2019
- Caplacizumab for Acquired Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2016
- Risk Factors for Intracerebral Hemorrhage in the General PopulationStroke, 2003